The increasingly challenging environment surrounding cardiovascular medicine has led to a number of companies exiting this area of research and a downturn in the number of clinical trials. But this doesn't spell the end of cardiovascular R&D.
List of topics covered:
- Why major companies are exiting cardiovascular R&D - Cardiovascular disease epidemiology; drivers of the cardiovascular drugs market - Generic competition and high-profile failures point to a tougher market - The cardiovascular disease clinical-trial slowdown - Anti-clotting agents - Reinventing aspirin - Cardiovascular market has room for new entrants - Atherosclerosis - Statins facing problems - CETP inhibitors - A2 phospholipase inhibitors - A vaccine for hypertension - Anti-arrhythmic drugs
